SCHEMBL247910

SCHEMBL247910

O=C(O)CC(CC(=O)O)(OC(=O)CC1(O)CC(=O)OC1=O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144693 0.77 AKR1B1 (0.33)
Water SCHEMBL8154773 0.75 AKR1B1 (0.33)
SCHEMBL23998056 0.72 AKR1B1 (0.33)
SCHEMBL22745719 0.71 CYP2C19 (0.49)
SCHEMBL21208412 0.70 CYP2C19 (0.51)
SCHEMBL23862377 0.70 CYP2C19 (0.51)
SCHEMBL14236451 0.69
SCHEMBL28142280 0.67 APEX1 (0.30)
SCHEMBL1989298 0.66 ALDH1A1 (0.39)
SCHEMBL8741818 0.66 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120088797-A1 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-12 US disclosed
US-20120035142-A1 POLYMORPHS OF DARUNAVIR MAPI PHARMA LIMITED (IL) 2012-02-09 US disclosed
EP-2412713-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2012-02-01 EP disclosed
US-20110288040-A1 ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-24 US disclosed
EP-2381786-A1 POLYMORPHS OF DARUNAVIR Mapi Pharma Limited (IL) 2011-11-02 EP disclosed
US-8048909-B2 Proton pump inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-01 US disclosed
EP-2369926-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES Takeda Pharmaceutical Company Limited (JP) 2011-10-05 EP disclosed
EP-1337525-B8 PROCESS FOR THE CRYSTALLIZATION OF (R)- OR (S)-LANSOPRAZOLE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
WO-2011070560-A1 PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS MAPI PHARMA HK LIMITED (CN) 2011-06-16 WO disclosed
US-20110144161-A1 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-16 US disclosed
EP-2327692-A1 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
WO-2011063150-A2 ORAL FORMULATION FOR DEXLANSOPRAZOLE HANDA PHARMACEUTICALS, LLC (US) 2011-05-26 WO disclosed
EP-1405621-B1 METHOD OF MANUFACTURING TABLET TAKEDA PHARMACEUTICAL (JP) 2011-05-11 EP disclosed
EP-1919865-B1 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2011-04-06 EP disclosed
EP-2292612-A2 Crystalline solvated forms of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole Takeda Pharmaceutical Company Limited (JP) 2011-03-09 EP disclosed
US-20110028476-A1 PROTON PUMP INHIBITORS KAJINO MASAHIRO 2011-02-03 US disclosed
EP-2275088-A2 Method for producing granules Takeda Pharmaceutical Company Limited (JP) 2011-01-19 EP disclosed
US-7871793-B2 Antimicrobial carbohydrates and methods of using same BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-01-18 US disclosed